Results You Can Trust Our medical team helps you maintain your results through nutrition and lifestyle guidance
Clinical trials involving positron emission tomography (PET) with translocator protein expressed by activated microglia (TSPO) have demonstrated that seizures, temporal lobe epilepsy, frontal lobe epilepsy, and focal cortical dysplasia are associated with neuroinflammation, and their acute onset leads to chronic neuroinflammation and exacerbates its deterioration (145)
However, because it is newer, clinicians review individual suitability carefully and monitor side effects closely
Healthcare professionals initiating retatrutide in clinical trial settings are advised to conduct a baseline mental health assessment and to maintain regular follow-up, in line with Health Research Authority (HRA) guidance and individual trial protocols
A recent CDC analysis found that only 11% of Medicaid recipients who meet clinical criteria for GLP-1 treatment were able to access the medication, compared to 38% of privately insured individuals
